bioAffinity Technologies, Inc. (BIAF) Price & Analysis

Compare

78 Followers

BIAF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.24 - $3.16

Previous CloseN/A

Volume17.91K

Average Volume (3M)19.56M

Market Cap

$9.86M

Enterprise Value$14.57M

Total Cash (Recent Filing)$83.11K

Total Debt (Recent Filing)$10.01M

Price to Earnings (P/E)―

Beta-2.71

Next Earnings

May 20, 2025

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding18,255,823

10 Day Avg. Volume57,859,514

30 Day Avg. Volume19,558,247

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.46

Price to Cash Flow (P/CF)-0.60

P/FCF Ratio0.00

Enterprise Value/Market Cap1.48

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit18.41

Enterprise Value/Ebitda-1.88

Forecast

1Y Price Target

$6.00

Price Target Upside1233.33% Upside

Rating ConsensusHold

Number of Analyst Covering1

---

bioAffinity Technologies, Inc. News

PremiumCompany Announcements

bioAffinity Technologies Board Member Announces Departure

17d ago

BIAF

PremiumCompany Announcements

bioAffinity Technologies Reports Record Revenue for 2024

24d ago

BIAF

PremiumThe Fly

BioAffinity Technologies downgraded to Hold from Buy at Maxim

1M ago

BIAF

PremiumPre-Earnings

BIAF Upcoming Earnings Report: What to Expect?

1M ago

BIAF

PremiumThe Fly

BioAffinity accelerates CyPath Lung amid $4M in annual cost savings at PPLS

2M ago

BIAF

PremiumThe Fly

BioAffinity patent application accepted by IP Australia for early stage LC test

3M ago

BIAF

PremiumCompany Announcements

bioAffinity Technologies Adjusts CEO Compensation Package

4M ago

BIAF

PremiumThe Fly

BioAffinity reports positive results from Texas beta launch of CyPath Lung

4M ago

BIAF

See All BIAF News

---

Bulls Say, Bears Say

Bulls Say

Commercialization StrategyEven without current FDA approval, BIAF’s commercialization strategy as an LDT is driving significant testing volume and revenue growth.

Market OpportunityCyPath Lung was added to the US Federal Supply Schedule, allowing VA and Military Health System physicians to order the test.

Product AdoptionThe number of physician offices offering the CyPath Lung test increased significantly, indicating growing adoption of the diagnostic test.

Bears Say

Financial StabilityThe company needs to raise additional capital immediately, which could lead to share dilution for current shareholders.

Profitability ConcernsDespite the novel diagnostic technology and market potential, the company's inability to operate profitably without raising additional funds is concerning.

Revenue GuidanceThe company introduced 2025 revenue guidance significantly below prior estimates, leading to a downgrade of the stock to Hold.

---

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

24.12% Insiders

1.88% Mutual Funds

0.27% Other Institutional Investors

72.25% Public Companies and

Individual Investors

Detailed Ownership Overview >

BIAF FAQ

What was bioAffinity Technologies, Inc.’s price range in the past 12 months?

bioAffinity Technologies, Inc. lowest stock price was $0.24 and its highest was $3.16 in the past 12 months.

What is bioAffinity Technologies, Inc.’s market cap?

bioAffinity Technologies, Inc.’s market cap is $9.86M.

When is bioAffinity Technologies, Inc.’s upcoming earnings report date?

bioAffinity Technologies, Inc.’s upcoming earnings report date is May 20, 2025 which is in 19 days.

How were bioAffinity Technologies, Inc.’s earnings last quarter?

bioAffinity Technologies, Inc. released its earnings results on Mar 31, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.16 by -$0.03.

Is bioAffinity Technologies, Inc. overvalued?

According to Wall Street analysts bioAffinity Technologies, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does bioAffinity Technologies, Inc. pay dividends?

bioAffinity Technologies, Inc. does not currently pay dividends.

What is bioAffinity Technologies, Inc.’s EPS estimate?

bioAffinity Technologies, Inc.’s EPS estimate is 0.

How many shares outstanding does bioAffinity Technologies, Inc. have?

bioAffinity Technologies, Inc. has 18,255,823 shares outstanding.

What happened to bioAffinity Technologies, Inc.’s price movement after its last earnings report?

bioAffinity Technologies, Inc. reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.16. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of bioAffinity Technologies, Inc.?

Currently, no hedge funds are holding shares in BIAF

---

Company Description

bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

---

BIAF Stock 12 Month Forecast

Average Price Target

$6.00

▲(1233.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","1.75":"$1.75","3.5":"$3.5","5.25":"$5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Jul<br/>2024","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.09,1.4676923076923079,1.8453846153846154,2.223076923076923,2.600769230769231,2.9784615384615387,3.3561538461538465,3.7338461538461543,4.111538461538462,4.48923076923077,4.866923076923078,5.2446153846153845,5.622307692307692,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.09,1.4676923076923079,1.8453846153846154,2.223076923076923,2.600769230769231,2.9784615384615387,3.3561538461538465,3.7338461538461543,4.111538461538462,4.48923076923077,4.866923076923078,5.2446153846153845,5.622307692307692,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.09,1.4676923076923079,1.8453846153846154,2.223076923076923,2.600769230769231,2.9784615384615387,3.3561538461538465,3.7338461538461543,4.111538461538462,4.48923076923077,4.866923076923078,5.2446153846153845,5.622307692307692,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.28,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.69,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.69,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.54,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.1,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.09,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.45,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.4,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.22,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.22,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >